Evidence map›Paper›PMID 29037604›Full record

ReviewEBioMedicine2017

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Giulia M Stella, Silvia Benvenuti, Alessandra Gentile, Paolo M Comoglio

Abstract readReview
In one paragraph

Review in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. [Expression of phosphoglycerate kinase 1 in endometrial carcinoma and its association with patients' outcome].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giulia M StellaCardiothoracic Dept., Section of Respiratory System Diseases, IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: g.stella@smatteo.pv.it.
Silvia BenvenutiCandiolo Cancer Institute, FPO-IRCCS, Str Prov 142, 10060 Candiolo, Italy.
Alessandra GentileCandiolo Cancer Institute, FPO-IRCCS, Str Prov 142, 10060 Candiolo, Italy.
Paolo M ComoglioCandiolo Cancer Institute, FPO-IRCCS, Str Prov 142, 10060 Candiolo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular and cellular mechanisms which drive metastatic spread are the topic of constant debate and scientific research due to the potential implications for cancer patients' prognosis. In addition to genetics and environmental factors, mechanics of single cells and physical interaction with the surrounding environment play relevant role in defining invasive phenotype. Reconstructing the physical properties of metastatic clones may help to clarify still open issues in disease progression as well as to lead to new diagnostic and therapeutic approaches. In this perspective cancer of unknown primary origin (CUP) identify the ideal model to study physical interactions and forces involved in the metastatic process. We have previously demonstrated that MET oncogene is mutated with unexpected high frequency in CUPs. We here analyze and discuss how the MET activation by somatic mutation may affect physical properties in giving rise to such a highly malignant syndrome, as that defined by CUP.

Indexed as

Transcriptional ActivationGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansMutationNeoplasm MetastasisNeoplasms, Unknown PrimaryPhenotypeProto-Oncogene Proteins c-metMET protein, humanProto-Oncogene Proteins c-metCancerInvasive growthMechanical forcesMetastasisMET oncogeneRheology

Identifiers

PMID29037604
PMCPMC5652293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.